蛤蚧定喘胶囊联合沙美特罗替卡松粉吸入剂治疗老年慢性阻塞性肺疾病稳定期的临床研究
|
摘要
目的研究蛤蚧定喘胶囊联合沙美特罗替卡松粉吸入剂治疗老年慢性阻塞性肺疾病稳定期的临床疗效。方法选取2015年1月—2017年6月内蒙古包钢医院收治的120例老年慢性阻塞性肺疾病稳定期患者为研究对象,将所有患者随机分为对照组和治疗组,每组各60例。对照组患者吸入沙美特罗替卡松粉吸入剂,1吸/次,2次/d。治疗组在对照组基础上口服蛤蚧定喘胶囊,3粒/次,2次/d。两组患者持续治疗3个月。观察两组的临床疗效,比较两组的肺功能指标、圣乔治呼吸疾病问卷(SGRQ)评分、6 min步行距离(6 MWD)、血清炎性因子水平。结果治疗后,对照组和治疗组的总有效率分别为81.67%、96.67%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者用力肺活量(FVC)、第一秒用力呼吸容积(FEV1)、FVC/FEV1水平显著升高,同组治疗前后比较差异有统计学意义(P<0.05);并且治疗组肺功能指标水平明显高于对照组,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者6 MWD显著升高,SGRQ评分显著降低,同组治疗前后比较差异有统计学意义(P<0.05);并且治疗组6 MWD和SGRQ评分明显优于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者降钙素原(PCT)和C反应蛋白(CRP)水平显著降低,同组治疗前后比较差异有统计学意义(P<0.05);并且治疗组血清炎性因子水平明显低于对照组,两组比较差异有统计学意义(P<0.05)。结论蛤蚧定喘胶囊联合沙美特罗替卡松粉吸入剂治疗老年慢性阻塞性肺疾病稳定期具有较好的临床疗效,能改善患者临床症状和肺功能,降低血清炎性因子水平,具有一定的临床推广应用价值。
Objective To study the effect of Gejie Dingchuan Capsules combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation in treatment of chronic obstructive pulmonary disease in the elderly at stable period. Methods Elderly patients(120 cases) with chronic obstructive pulmonary disease at stable period in Inner Mongolia Baotou Steel Hospital from January 2015 to June 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were inhaled administered with Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation, 1 inhalation/time, twice daily. Patients in the treatment group were po administered with Gejie Dingchuan Capsules on the basis of the control group, 3 grains/time, twice daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and pulmonary function indexes, SGRQ score, 6 MWD, and serum levels of inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.67% and 96.67%, respectively,and there was difference between two groups(P < 0.05). After treatment, the levels of FVC, FEV1, and FVC/FEV1 in two groups were significantly increased, and the difference was statistically significant in the same group(P < 0.05). And the pulmonary function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the 6 MWD in two groups were significantly increased, but the SGRQ scores in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05).After treatment, the levels of PCT and CRP in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And serum levels of inflammatory factors in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Gejie Dingchuan Capsules combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation has clinical curative effect in treatment of chronic obstructive pulmonary disease in the elderly at stable period, can improve the clinical symptoms and pulmonary function of patients, and reduce the level of serum inflammatory factors, which has a certain clinical application value.
Objective To study the effect of Gejie Dingchuan Capsules combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation in treatment of chronic obstructive pulmonary disease in the elderly at stable period. Methods Elderly patients(120 cases) with chronic obstructive pulmonary disease at stable period in Inner Mongolia Baotou Steel Hospital from January 2015 to June 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were inhaled administered with Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation, 1 inhalation/time, twice daily. Patients in the treatment group were po administered with Gejie Dingchuan Capsules on the basis of the control group, 3 grains/time, twice daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and pulmonary function indexes, SGRQ score, 6 MWD, and serum levels of inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.67% and 96.67%, respectively,and there was difference between two groups(P < 0.05). After treatment, the levels of FVC, FEV1, and FVC/FEV1 in two groups were significantly increased, and the difference was statistically significant in the same group(P < 0.05). And the pulmonary function indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups(P < 0.05). After treatment, the 6 MWD in two groups were significantly increased, but the SGRQ scores in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05).After treatment, the levels of PCT and CRP in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). And serum levels of inflammatory factors in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Gejie Dingchuan Capsules combined with Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation has clinical curative effect in treatment of chronic obstructive pulmonary disease in the elderly at stable period, can improve the clinical symptoms and pulmonary function of patients, and reduce the level of serum inflammatory factors, which has a certain clinical application value.
引文
[1]兰丰铃,王胜锋,曹卫华,等.慢性阻塞性肺疾病危险因素流行病学研究新进展[J].中华疾病控制杂志,2014,18(10):998-1002.
[2]蔡柏蔷.慢性阻塞性肺疾病发病机制的新进展[J].中华内科杂志,2000,39(3):204.
[3]陈宝春.痰热清注射液联合沙美特罗替卡松治疗慢性阻塞性肺疾病急性加重期的临床研究[J].现代药物与临床,2018,33(10):2571-2575.
[4]王聪颖,张庆,张阳,等.戒烟干预联合沙美特罗替卡松粉吸入剂治疗慢性阻塞性肺疾病的疗效观察[J].广东医学,2014,35(7):1053-1055.
[5]林丹曦.蛤蚧定喘胶囊治疗慢性阻塞性肺疾病疗效观察和经济学价值[J].临床内科杂志,2002,19(5):391-392.
[6]王蔚文.临床疾病诊断与疗效判断标准[M].北京:科学技术文献出版社,2010:129-130.
[7]陈秀利,刘扣英,孙培莉,等.稳定期COPD患者CAT评分与6 min步行距离相关性研究[J].护士进修杂志,2013,28(10):869-871.
[8]陈浩,王莹.圣乔治呼吸问卷评估慢性阻塞性肺疾病患者生活质量的价值[J].安徽医学,2014,35(8):1052-1054.
[9]单淑香,陈宝元.慢性阻塞性肺疾病流行病学研究进展[J].国际呼吸杂志,2005,25(6):440-442.
[10]康睿.鱼腥草注射液联合噻托溴铵和沙美特罗替卡松治疗缓解期慢性阻塞性肺疾病的临床研究[J].现代药物与临床,2016,31(9):1407-1411.
[11]冯艳,李国梁.沙美特罗替卡松干粉吸入剂联合噻托溴铵治疗慢性阻塞性肺疾病稳定期的临床疗效[J].中国医药导刊,2014,16(6):1026-1027,1029.
[12]喻俊颜.蛤蚧定喘胶囊对慢性阻塞性肺疾病稳定期BODE指数疗效的影响[J].医学信息:中旬刊,2011,24(8):4019.
[13]吴桦,曹宁家,尚立群,等.慢性阻塞性肺疾病患者C-反应蛋白与降钙素原水平的变化与意义[J].现代检验医学杂志,2013,28(5):39-41.
[2]蔡柏蔷.慢性阻塞性肺疾病发病机制的新进展[J].中华内科杂志,2000,39(3):204.
[3]陈宝春.痰热清注射液联合沙美特罗替卡松治疗慢性阻塞性肺疾病急性加重期的临床研究[J].现代药物与临床,2018,33(10):2571-2575.
[4]王聪颖,张庆,张阳,等.戒烟干预联合沙美特罗替卡松粉吸入剂治疗慢性阻塞性肺疾病的疗效观察[J].广东医学,2014,35(7):1053-1055.
[5]林丹曦.蛤蚧定喘胶囊治疗慢性阻塞性肺疾病疗效观察和经济学价值[J].临床内科杂志,2002,19(5):391-392.
[6]王蔚文.临床疾病诊断与疗效判断标准[M].北京:科学技术文献出版社,2010:129-130.
[7]陈秀利,刘扣英,孙培莉,等.稳定期COPD患者CAT评分与6 min步行距离相关性研究[J].护士进修杂志,2013,28(10):869-871.
[8]陈浩,王莹.圣乔治呼吸问卷评估慢性阻塞性肺疾病患者生活质量的价值[J].安徽医学,2014,35(8):1052-1054.
[9]单淑香,陈宝元.慢性阻塞性肺疾病流行病学研究进展[J].国际呼吸杂志,2005,25(6):440-442.
[10]康睿.鱼腥草注射液联合噻托溴铵和沙美特罗替卡松治疗缓解期慢性阻塞性肺疾病的临床研究[J].现代药物与临床,2016,31(9):1407-1411.
[11]冯艳,李国梁.沙美特罗替卡松干粉吸入剂联合噻托溴铵治疗慢性阻塞性肺疾病稳定期的临床疗效[J].中国医药导刊,2014,16(6):1026-1027,1029.
[12]喻俊颜.蛤蚧定喘胶囊对慢性阻塞性肺疾病稳定期BODE指数疗效的影响[J].医学信息:中旬刊,2011,24(8):4019.
[13]吴桦,曹宁家,尚立群,等.慢性阻塞性肺疾病患者C-反应蛋白与降钙素原水平的变化与意义[J].现代检验医学杂志,2013,28(5):39-41.